Vai al contenuto principale
Logo Università
Logo di PhD in Complex Systems for Quantitative Biomedicine

Doctoral school

PhD in Complex Systems for Quantitative Biomedicine

Logo di PhD in Complex Systems for Quantitative Biomedicine

Enrico Giraudo

Professor

Contacts

At

  • Department of Drug Science and Technology
  • Dipartimento di Scienza e Tecnologia del Farmaco
  • Corsi di studio in
    Farmacia - Chimica e tecnologia farmaceutiche
  • Dottorato in Sistemi Complessi per le Scienze della Vita (fino al ciclo 35) - PhD Programme in Complex Systems for Life Sciences (until 35th cycle)
  • PhD in Complex Systems for Quantitative Biomedicine
  • PhD Programme in Complex Systems for Life Sciences (until 35th cycle)

Curriculum vitae

  • Curriculum Vitae (0.3 MB)

    • Selected research products

    Impact factor (IF) and Times of Citation according to the ISI Web of Science and the SCOPUS citation database.

    Up to January 2024, Enrico Giraudo has an h-index of 37 (h-index of 37 and a total of 6679 citations; i10-H index of 51 based on Google scholar); a number of total citations of the global scientific production of 5180; a total Impact Factor (IF) of 709,532  and an Average IF per paper of 13.387. He's co-author in a book chapter; he has been invited for lecture or seminar up to 20 and he presented 58 abstract and proceedings to national and international congress. Moreover Giraudo has been co-organizer of an international workshop in Leiden, The Netherlands.

    1) Franzolin G, Brundu S, Cojocaru CF, Curatolo A, Ponzo M, Mastrantonio R, Mihara E, Kumanogoh A, Suga H, Takagi J, Tamagnone L, Giraudo E*. PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination. Cancer Immunol Res. 2024 Sep 3;12(9):1286-1301. doi: 10.1158/2326-6066.CIR-23-0289.*Last and Corresponding author. IF: 8,1

    2) Fard D, Giraudo E, Tamagnone L. Mind the (guidance) signals! Translational relevance of semaphorins, plexins, and neuropilins in pancreatic cancer. Trends Mol Med. 2023 Oct;29(10):817-829. doi: 10.1016/j.molmed.2023.07.009. Epub 2023 Aug 17. IF: 12,8

    3) Martino F, Lupi M, Giraudo E, Lanzetti L. Breast cancers as ecosystems: a metabolic perspective. Cell Mol Life Sci. 2023 Aug 10;80(9):244. doi: 10.1007/s00018-023-04902-9. IF: 6,2

    4) Brundu S, Napolitano V, Franzolin G, Lo Cascio E, Mastrantonio R, Sardo G, Cascardi E, Verginelli F, Sarnataro S, Gambardella G, Pisacane A, Arcovito A, Boccaccio C, Comoglio PM, Giraudo E*, Tamagnone L. EMBO Mol Med. 2023 Feb 1:e16104. doi: 10.15252 / emmm. 202216104. *Co-last and Co-corresponding author. IF (ISI WOS 2022):14.005

    5) Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, Cascone I. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers (Basel). 2022 Aug 31;14(17):4265. doi: 10.3390/cancers14174265. *Co-last author. IF (ISI WOS 2022):6.575

    6) Gioelli N, Neilson LJ, Wei N, Villari G, Chen W, Kuhle B, Ehling M, Maione F, Willox S, Brundu S, Avanzato D, Koulouras G, Mazzone M, Giraudo E, Yang XL, Valdembri D, Zanivan S, Serini G. Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability. Nat Commun. 2022 Jul 20;13(1):4188. doi: 10.1038/s41467-022-31904-1. IF (ISI WOS 2022):17.694

    7) Sainas S, Giorgis M, Circosta P, Gaidano V, Bonanni D, Pippione AC, Bagnati R, Passoni A, Qiu Y, Cojocaru CF, Canepa B, Bona A, Rolando B, Mishina M, Ramondetti C, Buccinnà B, Piccinini M, Houshmand M, Cignetti A, Giraudo E, Al-Karadaghi S, Boschi D, Saglio G, Lolli ML. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety. J Med Chem. 2021; May 13; 64(9):5404-5428. doi: 10.1021/acs.jmedchem.0c01549. IF (ISI WOS 2021): 7.446. Citazioni: 1.

    8) Federica Bessone, Chiara Dianzani, Monica Argenziano, Luigi Cangemi, Rita Spagnolo, Federica Maione, Enrico Giraudo and Roberta Cavalli. Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance. Cancer Drug Resist 2020; Head of print. 2021, 4 (1): 192-207. http://dx.doi.org/10.20517/cdr.2020.65. Citazioni: 1

    9) Zhuang X, Maione F, Robinson J, Bentley M, Kaul B, Whitworth K, Jumbu N, Jinks E, Bystrom J, Gabriele P, Garibaldi E, Delmastro E, Nagy Z, Gilham D, Giraudo E, Bicknell R, Lee SP. CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth JCI Insight. 2020, Oct 2; 5(19):e138808. doi: 10.1172/jci.insight.138808. IF (ISI WOS 2021): 8.315. Citazioni: 3

    10) Yaqi Qiu, Federica Maione, Stefania Capano, Claudia Meda, Orietta Picconi, Serena Brundu, A lberto Pisacane, Anna Sapino, Clelia Palladino, Giovanni Barillari, Paolo Monini, Federico Bussolino, Barbara Ensoli, Cecilia Sgadari, and Enrico Giraudo. HIV-protease inhibitors block HPV16-induced murine cervical carcinoma and promote vessel normalization in association with MMP-9 inhibition and TIMP-3 induction. Mol Cancer Ther, 2020; 19(12):2476–89. doi: 10.1158/1535-7163.MCT-20-0055. Corresponding author. IF (ISI WOS 2021): 6.261

    11) Sandra Atlante, Alessia Visintin, Elisabetta Marini, Matteo Savoia, Chiara Dianzani, Marta Giorgis, Duran Sürün, Federica Maione, Frank Schnütgen, Antonella Farsetti, Andreas M. Zeiher, Massimo Bertinaria, Enrico Giraudo, Francesco Spallotta, Chiara Cencioni and Carlo Gaetano. α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death Dis. 2018; 9(7):756. doi: 10.1038/s41419-018-0802-8. IF (ISI WOS 2021): 8.469. Citazioni: 21.

    12) Noemi Gioelli, Federica Maione, Chiara Camillo, Michela Ghitti, Donatella Valdembri, Noemi Morello, Marie Darche, Lorena Zentilin, Gabriella Cagnoni, Yaqi Qiu, Mauro Giacca, Maurizio Giustetto, Michel Paques, Ilaria Cascone, Giovanna Musco, Luca Tamagnone, Enrico Giraudo*, Guido Serini*. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci Transl Med. 2018; 10(442):eaah4807. doi: 10.1126/scitranslmed.aah4807. *Co-Corresponding author and Co-last author.  IF (ISI WOS 2021): 17, 956. Citazioni: 25.

    13) Dettori D, Orso F, Penna E, Baruffaldi D, Brundu S, Maione F, Turco E, Giraudo E, Taverna D. Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. Mol Ther. 2018; 26(8):2008-2018. doi: 10.1016/j.ymthe.2018.05.020. IF (ISI WOS 2021): 11.454. Citazioni: 13.

    14) Kunita A, Baeriswyl V, Meda C, Cabuy E, Takeshita K, Giraudo E, Wicki A, Fukayama M, Christofori G. Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front. Am J Pathol. 2018; 188(5):1276-1288. doi: 10.1016/j.ajpath.2018.01.016. Epub 2018 Feb 17. IF (ISI WOS 2021): 4.307. Citazioni: 11.

    15) Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017; 552(7683):116-120. doi: 10.1038/nature24673. IF (ISI WOS 2021): 49,962. Citazioni: 216.

    16) Zoi Diamantopoulou, Maud-Emmanuelle Gilles, Maha Sader, Mélissande Cossutta, Benoit Vallée, Claire Houppe, Damien Habert, Blandine Brissault, Eric Leroy, Federica Maione, Enrico Giraudo, Damien Destouches, Jacques Penelle, José Courty1, and Ilaria Cascone. Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy. Oncotarget. 2017; 8(52):90108-90122. doi: 10.18632/oncotarget.21441. eCollection 2017. IF (ISI WOS 2017): 5.168. Citazioni: 11.

    17) Regano D, Visintin A, Clapero F, Bussolino F, Valdembri D, Maione F, Serini G, *Giraudo E. Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program. Arterioscler Thromb Vasc Biol. 2017; Sep; 37(9):1710-1721. doi: 10.1161/ATVBAHA.117.308226. *Corresponding author and last author. IF (ISI WOS 2021): 8,311. Citazioni: 5.

    18) Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, Houppe C, Destouches D, Shchors K, Prochasson C, Mongelard F, Lamba S, Bardelli A, Bouvet P, Couvelard A, Courty J, Giraudo E*, Cascone I*. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 2016; Dec 15; 76(24):7181-7193. doi: 10.1158/0008-5472.CAN-16-0300. *Co-Corresponding author and Co-last author. IF (ISI WOS 2021): 12,701. Citazioni: 52.

    19) Avanzato D, Genova T, Fiorio Pla A, Bernardini M, Bianco S, Bussolati B, Mancardi D, Giraudo E, Maione F, Cassoni P, Castellano I, Munaron L.  Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling. Sci Rep. 2016; Sep 2; 6:32602. doi: 10.1038/srep32602. IF (ISI WOS 2021): 4.379. Citazioni: 40.

    20) Valdembri D, Regano D, Maione F, Giraudo E*, Serini G. Class 3 semaphorins in cardiovascular development Cell Adh Migr. 2016; Nov; 10(6):641-651. doi: 10.1080/19336918.2016.1212805.  *Co-Corresponding author and Co-last author. IF (ISI WOS 2021): 3.405. Citazioni: 20.

    21) Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med. 2016; May 5; 14(1):119. doi: 10.1186/s12967-016-0872-2. IF (ISI WOS 2021): 5.531;. Citazioni: 8.

    22) Federica Maione, Simonetta Oliaro-Bosso, Claudia Meda, Federica Di Nicolantonio, Federico Bussolino, Gianni Balliano, *Franca Viola and Enrico Giraudo*. The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.  Sci. Rep. 2015; Mar 12; 5:9054; doi:10.1038/srep09054. *Corresponding author. IF (ISI WOS 2021): 4.379. Citazioni: 26.

    23) Federica Maione and Enrico Giraudo. Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer. Methods Mol Biol., 2015; 1267:349-65. doi: 10.1007/978-1-4939-2297-0_17. Citazioni: 6. Sopus :2-s2.0-84954582641. *Last and Co-corresponding author 

    24) Patella F, Schug ZT, Persi E, Neilson LJ, Erami Z, Avanzato D, Maione F, Hernandez-Fernaud JR, Mackay G, Zheng L, Reid S, Frezza C, Giraudo E, Fiorio Pla A, Anderson K, Ruppin E, Gottlieb E, Zanivan S. Proteomics-based metabolic modelling reveals that fatty acid oxidation controls endothelial cell permeability. Mol Cell Proteomics. 2015. Mar; 14(3):621-34. doi: 10.1074/mcp.M114.045575. IF (ISI WOS 2021): 5,911. Citazioni: 55.

    25) Corà D, Astanina E, Giraudo E, Bussolino F. Semaphorins in cardiovascular medicine. Trends Mol Med. 2014; Oct; 20(10):589-98. doi: 10.1016/j.molmed.2014.07.005. IF (ISI WOS 2021): 11.951. Citazioni: 10.

    26) Valetti S, Maione F, Mura S, Stella B, Desmaële D, Noiray M, Vergnaud J, Vauthier C, Cattel L,Giraudo E, Couvreur P. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. J Control Release. 2014; Oct, 28;192:29-39. doi: 10.1016/j.jconrel.2014.06.039. IF (ISI WOS 2021): 9.776. Citazioni: 43.

    27) Bussolino F, Giraudo E, Serini G. Class 3 semaphorin in angiogenesis and lymphangiogenesis. Chem Immunol Allergy. 2014; 99:71-88. doi: 10.1159/000353315. Citazioni: 10. Scopus: 2-s2.0-84904229357

    28) Zanivan S, Maione F, Hein MY, Hernández-Fernaud JR, Ostasiewicz P, Giraudo E, Mann M. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics. 2013; Dec; 12(12):3599-611. doi: 10.1074/mcp.M113.031344. IF (ISI WOS 2021): 5,911. Citazioni: 45.

    29) Gu C, Giraudo E*. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res. 2013; May 15; 319(9):1306-16. doi: 10.1016/j.yexcr.2013.02.003. *Corresponding author. IF (ISI WOS 2021):  3,905.  Citazioni: 78. 

    30) Guido Serini, Federico Bussolino, Federica Maione and Enrico Giraudo*. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. J. Intern. Med. 2013; Feb; 273(2):138-55.  doi: 10.1111/joim.12017. * Corresponding author. IF (ISI WOS 2021): 8.989. Citazioni: 32.

    31) Carrer A, Moimas S, Zacchigna S, Pattarini L, Zentilin L, Ruozzi G, Mano M, Sinigaglia M, Maione F, Serini G, Giraudo E, Bussolino F, Giacca M. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res, 2012, Dec 15; 72:6371-6381. doi: 10.1158/0008-5472.CAN-12-0762.  IF (ISI WOS 2021): 12,701. Citazioni: 43.

    32) Napione L, Strasly M, Meda C, Mitola S, Alvaro M, Doronzo G, Marchiò S, Giraudo E, Primo L, Arese M, Bussolino F.  IL-12-dependent innate immunity arrests endothelial cells in G0-G1 phase by a p21(Cip1/Waf1)-mediated mechanism. Angiogenesis. 2012; Dec; 15(4):713-25. doi: 10.1007/s10456-012-9286-9. IF (ISI WOS 2021): 9.596. Citazioni: 3.

    33) Federica Maione, Stefania Capano, Donatella Regano, Lorena Zentilin, Mauro Giacca, Oriol Casanovas, Federico Bussolino, Guido Serini, and Enrico Giraudo1. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 2012; May 1; 122(5):1832-48. doi: 10.1172/JCI58976. 1 Corresponding author. IF (ISI WOS 2021): 14.808. Citazioni: 123.

    34) Claudia Meda, Fabiola Molla, Maria De Pizzol, Donatella Regano, Federica Maione, Stefania Capano, Massimo Locati, Alberto Mantovani, Roberto Latini, Federico Bussolino and Enrico Giraudo1. Sema4A exerts a pro-angiogenic effect by enhancing VEGF-A expression in macrophages. J. Immunol. 2012; Apr 15; 188 (8); 4081-92. doi: 10.4049/jimmunol.1101435. 1 Corresponding author. IF (ISI WOS 2021): 5,422. Citazioni: 48.

    35) Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med. 2012; Mar; 4(3):234-50. doi: 10.1002/emmm.201100205. IF (ISI WOS 2021): 12.137. Citazioni: 69.

    36) Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. (2011);  Feb; 47(3):479-90. doi: 10.1016/j.ejca.2010.10.003. IF (ISI WOS 2021): 9.162. Citazioni: 37.

    37) Primo L, Seano G, Roca C, Maione F, Gagliardi PA, Sessa R, Martinelli M, Giraudo E, di Blasio L, Bussolino F. Increased expression of α6 integrin in endothelial cells unveils a proangiogenic role for basement membrane. Cancer Res. 2010; Jul; 70(14): 5759-69. doi: 10.1158/0008-5472.CAN-10-0507. IF (ISI WOS 2021): 12,701. Citazioni: 41.

    38) Federica Maione, Fabiola Molla, Roberto Latini, Lorena Zentilin, Mauro Giacca, Claudia Meda, Giorgio Seano, Guido Serini, Federico Bussolino and Enrico Giraudo1. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin.Invest. 2009; Nov; 119(11): 3356-72. doi: 10.1172/JCI36308. 1 Corresponding author. IF (ISI WOS 2021): 14.808. Citazioni: 166.

    39) Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto G. Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol. Lipids. 2009; Oct; 44(10):907-916. doi: 10.1007/s11745-009-3338-y. IF (ISI WOS 2021): 1.880. Citazioni: 46.

    40) Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. Angiogenesis, 2009; May, 12(2):195. Erratum to: Angiogenesis DOI 10.1007/s10456-009-9138-4; 2009;12(2):187-93. doi: 10.1007/s10456-009-9138-4. IF (ISI WOS 2021): 9.596. Citazioni: 41.

    41) Francesca Orso, Elisa Penna, Daniela Cimino, Elena Astanina, Federica Maione, Donatella Valdembri, Enrico Giraudo, Guido Serini, Piero Sismondi, Michele De Bortoli and Daniela Taverna. AP-2a and AP-2g Regulate Epithelial Tumor Progression via Specific Genetic Programs. FASEB J, 2008; Aug, 22(8):2702-14. doi: 10.1096/fj.08-106492. IF (ISI WOS 2021): 5.191. Citazioni: 52.

    42) Lianglin Zhang, Enrico Giraudo, Jason A. Hoffman, Douglas Hanahan and Erkki Ruoslahti. Lymphatic Zip Codes in Tumors and Premalignant Lesions. Cancer Res. 2006; Jun 1; 66(11):5696-706. doi: 10.1158/0008-5472.CAN-05-3876. IF (ISI WOS 2020): 12,701. Citazioni: 61.

    43) Dylan Daniel, Christopher Chiu, Enrico Giraudo, Masahiro Inoue, Lee A. Mizzen, N. Randall Chu and Douglas Hanahan. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005; Mar 1, 65(5):2018-25. doi: 10.1158/0008-5472.CAN-04-3444. IF (ISI WOS 2020): 12,701. Citazioni: 65.

    44) Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis". J. Clin. Invest. (2004); Sep 1, 114(5):623-33. doi: 10.1172/JCI22087. IF (ISI WOS 2020): 14.808. Citazioni: 522.

    45) Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; May, 5(5):443-53; doi: 10.1016/s1535-6108(04)00111-4. IF (ISI WOS 2021): 31.743. Citazioni: 481. 

    46) Hoffman JA*, Giraudo E*, Singh M, Zhang L, Inoue M, Porkka K, Hanahan D, Ruoslahti E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 2003; Nov, 4(5):383-91. doi: 10.1016/s1535-6108(03)00273-3. *First author co-autorship.  IF (ISI WOS 2021): 31.743. Citazioni: 180. 

    47) Ilaria Cascone *, Enrico Giraudo *, Francesca Caccavari, Lucia Napione, Elisa Bertotti, John G. Collard, Guido Serini and Federico Bussolino. Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network. Adherens junctions and myosin light chain as targets of Rac1 and RhoA. J Biol Chem. 2003; Dec, 278(50):50702-13. doi: 10.1074/jbc.M307234200. * First author co-autorship. IF (ISI WOS 2021): 5,517. Citazioni: 65. 

    48) Cascone I, Audero E, Giraudo E, Napione L, Maniero F, Philips MR, Collard JG, Serini G, Bussolino F. Tie-2 - dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood. 2003; Oct 1, 102(7):2482-90. doi: 10.1182/blood-2003-03-0670. IF (ISI WOS 2021): 22.113. Citazioni: 47. 

    49) Serini G*, Ambrosi D*, Giraudo E* Gamba A*, Preziosi L, Bussolino F. "Modeling the early stages of vascular network assembly". EMBO J. (2003); Apr, 22(8):1771-9. doi: 10.1093/emboj/cdg176. *First author co-autorship. IF (ISI WOS 2021): 11.598. Citazioni: 230. 

    50) Corallini A, Possati L, Trabanelli C, Giraudo E, Rocchetti R, Talevi S, Caputo A, Bussolino F, Barbanti-Brodano G.. Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-b1. Carcinogenesis. 2003; 24(9):1435-44. doi: 10.1093/carcin/bgg096. IF (ISI WOS 2021): 4.944. Citazioni: 8.

    51) Gamba A, Ambrosi D, Coniglio A, de Candia A, Di Talia S, Giraudo E, Serini G, Preziosi L, Bussolino F. Percolation, morphogenesis, and burgers dynamics in blood vessels formation. Phys Rev Lett. 2003; Mar 21; 90(11):118101. doi: 10.1103/PhysRevLett.90.118101. IF (ISI WOS 2020): 9.161. Citazioni: 166.

    52) Del Sorbo, M. Arese, Giraudo E., M. Tizzani, L. Biancone, F.Bussolino, G.Camussi. "Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol. 2001; Feb; 31(2):376-383. doi: 10.1002/1521-4141(200102)31:2<376::aid-immu376>3.0.co;2-5. IF (ISI WOS 2021):  5.532. Citazioni: 22.

    53) Cutrupi S, Baldanzi G, Gramaglia D, Maffe A, Schaap D, Giraudo E, van Blitterswijk W, Bussolino F, Comoglio PM, and Graziani A. "Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility". EMBO J. 2000; Sep 1; 19(17):4614-22. doi: 10.1093/emboj/19.17.4614. IF (ISI WOS 2021): 11.598. Citazioni: 79.

    54) Giraudo E., Primo L., Audero E., Gerber HP, Koolwijk P., Soker S., Klagsbrun M Ferrara N, and. Bussolino F. "Tumor necrosis factor-a regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells". J. Biol. Chem., 1998; Aug 21; 273(34):22128-35. doi: 10.1074/jbc.273.34.22128. IF (ISI WOS 2021): 5,157. Citazioni: 229.

    55) A. Albini, R. Soldi, D. Giunciuglio, E. Giraudo, R. Benelli, L. Primo, D. Noonan, M. Salio, G. Camussi, W. Rockl and F. Bussolino. "The angiogenesis induced by HIV-1 Tat protein is mediated by the flk-1/KDR receptor on vascular endothelial cells". Nature Med. 1996, Dec; 2(12):1371-75. doi: 10.1038/nm1296-1371. IF (ISI WOS 2020): 36.130. Citazioni: 333.

    56) Giraudo E., M. Arese, C Toniatti, M Stransly, L Primo, A Mantovani, G Ciliberto and F. Bussolino. "Interleukin-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells." J. Immunol. 1996; Sep 15; 157(6):2618-23; WOS:A1996VL10300049; ISSN: 1550-6606. IF (ISI WOS 2021): 5,422. Times cited: 52.

    57) F. Silvagno, A. Follenzi, M. Arese, M. Prat, E. Giraudo, G. Gaudino, G. Camussi, P. M. Comoglio, F. Bussolino. "In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis". Arterioscler. Thromb. Vasc. Biol. 1995; Nov; 15(11):1857-65. doi: 10.1161/01.atv.15.11.1857. IF (ISI WOS 2021): 8,311. Times cited: 85. 

     

    Book chapters

    Federica Maione and Enrico Giraudo*. Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer. Methods Mol. Cell. Biol., 2015. vol. 1267:349-65. doi: 10.1007/978-1-4939-2297-0_17.* Corresponding author.

     

    Toulouse, France, 23-24 Ottobre 2019. Pancreatic Cancer Symposium, Association Française Pour La Recherche Sur Le Cancer Du Pancréas (AFRC). relatore su invito, titolo del seminario: Targeting Semaphorin4A-expressing myeloid cells to impair the progression of pancreatic ductal adenocarcinoma.

    Baveno, Italy, 25-28 Maggio 2019. Embo Workshop- Neural guidance molecules in development and disease; relatore su invito, titolo del seminario: Targeting Semaphorin4A-expressing myeloid cells to impair cancer progression”.

    Reims, France, 14-16 Ottobre 2018. 8eme Congrès de la Société Française d’Angiogenèse 2018. Relatore su invito; titolo del seminario: “Targeting Semaphorins to normalize the tumor vasculature and block the metastatic growth”.

     Paris, France 20-22 Settembre 2018.  ImmunoRad - the international conference on immunotherapy radiotherapy combination; relatore su invito, titolo del seminario: “Macrophages reprogramming modulates the immune tumor microenvironment in mouse models of HPV-driven cervical cancer”.

    1. Lausanne, Svitzerland, October 6th 2015. ISREC/SCCL special seminar. Seminario dal titolo: "Macrophage "re-education" induced by zoledronic acid impairs tumor angiogenesis and metastatic dissemination in a mouse model of spontaneous cervical cancer".

    2. S. Diego, CA, USA, aprile 5-9, 2014. 105rd AACR Annual Meeting 2014. Symposium "Tumor angiogenesis". Seminario dal titolo: "Zoledronic acid overcomes the resistance to the anti-angiogenic therapy and normalizes tumor vessels by switching from a M2- to a M1-like macrophages phenotype in a mouse model of spontaneous cervical cancer".

    3. Amsterdam, The Netherlands 12-14 Marzo 2014. 5th International Meeting on Angiogenesis, VU University Medical Center. Seminario dal titolo: "Zoledronic acid normalizes tumor vessels and blocks metastasis formation by skewing macrophages from a M2 to an M1-like phenotype in a mouse model of spontaneous cervical cancer.

     

    4. Pontignano, Siena, Italia, 13-15 maggio 2013. Angiogenesi: basi molecolari e implicazioni terapeutiche IV. Seminario dal titolo: " Sema 3A: a new tool to normalize the tumor vasculature and to impair metastasi dissemination".

    5. Lausanne, Switzerland, 5 Febbraio 2013. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences. Swiss Federal Institute of Technology Lausanne (EPFL). Lecture dal titolo " Semaphorin 3A: a new tool to "normalize" the tumor microenvironment and to block metastasis dissemination".

    6. Trieste, Italia, Novembre 29 2012. International Centre for Genetic Engineering and Biotechnology (ICGEB). Seminario dal titolo: "Semaphorin 3A: a new tool to normalize the tumor vasculature and to block metastasi dissemination".

    7. Chicago, Illinois, USA, 31 marzo- 4 aprile, 2012. 103rd AACR Annual Meeting 2012. Major Symposium "Vascular Reprogramming to improve Clinical Outcome". Seminario dal titolo: "Targeting semaphorin 3A: a new tool to normalize tumor vasculature and to overcome the evasive resistance to antiangiogenic therapy".   

    8. Lausanne, Switzerland, 7-10 settembre 2011. SREC Symposium 2011 Hallmarks and Horizons of Cancer. Seminario dal titolo: "Semaphorin 3A blocks cancer invasiveness and metastases dissemination induced by the anti-angiogenic therapy by overcoming tumor hypoxia".

    9. Pontignano, Italia, 10-12 maggio 2010. Workshop SIICA, "Angiogenesi: basi molecolari ed implicazioni terapeutiche III". Seminario dal titolo: "In vivo targeting semaphorins: new tools to control tumor angiogenesis and tumor invasiveness".

    10. Lausanne, Switzerland, 2 Febbraio 2010. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences. Swiss Federal Institute of Technology Lausanne (EPFL). Lecture dal titolo: "In vivo targeting semaphorins: new tools to control tumor angiogenesis".

    11. Roma, Italia, 15-16 gennaio 2010. International Conference "in memory of Judah Folkman "Update on angiogenesis: translational research". Seminario dal titolo: "In vivo targeting semaphorins: new tools to control tumour angiogenesis".

    12. Parigi, Francia, 27 aprile 2009. Marie Curie Institute, Parigi; Lecture dal titolo: " In vivo targeting semaphorins: new tools to control tumor angiogenesis."

    13. Roma, Italia, 24 gennaio 2009. "Update on Angiogenesis: One year from the departure of Judah Folkman". Seminario dal titolo: "Semaphorins and tumor angiogenesis".

    14. San Francisco, CA, USA, 12-15 gennaio 2009. "Mouse Models of Cancer", AACR special conference in cancer Research. Seminario dal titolo: "Semaphorin 3A Regulates Angiogenesis and Tumor Progression in Mouse Models of Tumorigenesis".

    15. Riccione, Italia 26-28 settembre 2007. Congresso SIB2007. "Cellular Biochemistry". Seminario dal titolo: "Role of class 3 semaphorins in tumor angiogenesis in transgenic mouse models of carcinogenesis".

    16. Rod Island, Newport, USA, 19-24 Agosto 2007. Salve Regina University, Gordon Conference on Angiogenesis. Seminario dal titolo: "Role of class 3 semaphorins in tumor angiogenesis in transgenic mouse models of pancreatic and cervical carcinogenesis".

    17. Riccione, Italia 28-30 settembre 2006. Congresso SIB2007. "Cellular Biochemistry". Seminario dal titolo: "Molecular changes in lymphatic vessels during tumor progression"

    18. Davos, Switzerland, 22 - 25 marzo, 2006. Eighth and Valedictory Workshop on Bisphosphonates From the Laboratory to the Patient. Seminario dal titolo: "Anti-angiogenic effects of bisphosphonates".

    19. Cervo Ligure, Italy, 6-8 ottobre 2005. Cervo Preclinical Working Conference (CPWC). Seminario dal titolo: "Aminobisphosphonates inhibit angiogenesis and impairs carcinogenesis in a mouse model of cervical carcinogenesis".

    20. Milano, Italia, 11-14 marzo, 2004. "First IEO-IFOM meeting on cancer". Seminario dal titolo: "A bisphosphonate inhibits angiogenesis and impairs cervical carcinogenesis by targeting MMP-9 activity and its expression in infiltrating macrophages".  

    Organized Meetings, conferences and workshop

     Workshop at Lorenz Center, October 4-8th 2010, Leiden, The Netherlands. Scientific organizer of the workshop: "Modelling angiogenesis: joining cells, maths and computers".

    Courses

    Research topics

    Research topic

    The laboratory is focused on discovering new targets and molecular mechanisms for anti-angiogenic therapies.

    Background

    Angiogenesis is required for invasive tumor growth and metastasis. Despite the development of innovative anti-angiogenic strategies, clinical trials have not replicated the results observed from preclinical models and resistance to anti-VEGF therapy has been recently observed in both preclinical and clinical trials. Hence, there is a need to identify new angiogenic modulators and mechanisms. Axon guidance cues, such as semaphorins and their receptors have been firstly identified in determining the proper neural connection during brain development. Recently, it has been demonstrated that they are involved in tumor angiogenesis and growth. However, the orchestrated roles played by these molecules and how they act in tumor vascularization and tumor invasion are essentially unknown.

    Achievements

    By employing transgenic mouse models of spontaneous pancreatic (RipTag2), cervical (K14-HPV16/E2) and skin (K14-HPV16) carcinogenesis we have found that Sema3A is an endogenous angiogenesis inhibitor, lost during tumor progression. Re-expression of Sema3As in RipTag2 tumors using AAV8 delivery system inhibited angiogenesis, cancer growth, normalized tumor vessels and restored tumor normoxia. We have more recently shown that the treatment of RIP-Tag2 and cervical carcinomas (HPV16/E2) mouse models with AAV8-Sema3A, by improving cancer tissue oxygenation and extending the normalization window, counteracted Sunitinib- and DC101 (anti-VEGFR2 antibody)- induced evasive resistance to the therapy by inhibiting tumor metastasis and, consequently, enhancing the survival. Importantly, Sema3A, by normalizing tumor vessels, efficiently improved the delivery of chemotherapeutic drugs to the tumors.

     
    Goals
    We plan (i) to employ Sema3A super-agonists mutants as a new compound to overcome the evasive resistance to the anti-angiogenic therapies, to halt metastasis formation and to normalize tumor vessels; (ii) to assess the efficacy of combining Sema3s or other axon guidance cues delivery with conventional anti-angiogenic drugs to block metastases  dissemination using different mouse models of cancer; (iii) to identify the mechanisms by which Semas, their receptors and other axon guidance cues regulate "stroma" normalization, tumor invasiveness and metastases formation.

     

     

    Impact factor (IF) and Times of Citation according to the ISI Web of Science and the SCOPUS citation database.

    Up to January 2024, Enrico Giraudo has an h-index of 37 (h-index of 37 and a total of 6679 citations; i10-H index of 51 based on Google scholar); a number of total citations of the global scientific production of 5180; a total Impact Factor (IF) of 709,532  and an Average IF per paper of 13.387. He's co-author in a book chapter; he has been invited for lecture or seminar up to 20 and he presented 58 abstract and proceedings to national and international congress. Moreover Giraudo has been co-organizer of an international workshop in Leiden, The Netherlands.

    1) Fard D, Giraudo E, Tamagnone L. Mind the (guidance) signals! Translational relevance of semaphorins, plexins, and neuropilins in pancreatic cancer. Trends Mol Med. 2023 Oct;29(10):817-829. doi: 10.1016/j.molmed.2023.07.009. Epub 2023 Aug 17.

    2) Martino F, Lupi M, Giraudo E, Lanzetti L. Breast cancers as ecosystems: a metabolic perspective. Cell Mol Life Sci. 2023 Aug 10;80(9):244. doi: 10.1007/s00018-023-04902-9.

    3) Brundu S, Napolitano V, Franzolin G, Lo Cascio E, Mastrantonio R, Sardo G, Cascardi E, Verginelli F, Sarnataro S, Gambardella G, Pisacane A, Arcovito A, Boccaccio C, Comoglio PM, Giraudo E*, Tamagnone L. EMBO Mol Med. 2023 Feb 1:e16104. doi: 10.15252 / emmm. 202216104. *Co-last and Co-corresponding author. IF (ISI WOS 2022):14.005

    4) Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, Cascone I. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers (Basel). 2022 Aug 31;14(17):4265. doi: 10.3390/cancers14174265. *Co-last author. IF (ISI WOS 2022):6.575

    5) Gioelli N, Neilson LJ, Wei N, Villari G, Chen W, Kuhle B, Ehling M, Maione F, Willox S, Brundu S, Avanzato D, Koulouras G, Mazzone M, Giraudo E, Yang XL, Valdembri D, Zanivan S, Serini G. Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability. Nat Commun. 2022 Jul 20;13(1):4188. doi: 10.1038/s41467-022-31904-1. IF (ISI WOS 2022):17.694

    6) Sainas S, Giorgis M, Circosta P, Gaidano V, Bonanni D, Pippione AC, Bagnati R, Passoni A, Qiu Y, Cojocaru CF, Canepa B, Bona A, Rolando B, Mishina M, Ramondetti C, Buccinnà B, Piccinini M, Houshmand M, Cignetti A, Giraudo E, Al-Karadaghi S, Boschi D, Saglio G, Lolli ML. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety. J Med Chem. 2021; May 13; 64(9):5404-5428. doi: 10.1021/acs.jmedchem.0c01549. IF (ISI WOS 2021): 7.446. Citazioni: 1.

    7) Federica Bessone, Chiara Dianzani, Monica Argenziano, Luigi Cangemi, Rita Spagnolo, Federica Maione, Enrico Giraudo and Roberta Cavalli. Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance. Cancer Drug Resist 2020; Head of print. 2021, 4 (1): 192-207. http://dx.doi.org/10.20517/cdr.2020.65. Citazioni: 1

    8) Zhuang X, Maione F, Robinson J, Bentley M, Kaul B, Whitworth K, Jumbu N, Jinks E, Bystrom J, Gabriele P, Garibaldi E, Delmastro E, Nagy Z, Gilham D, Giraudo E, Bicknell R, Lee SP. CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth JCI Insight. 2020, Oct 2; 5(19):e138808. doi: 10.1172/jci.insight.138808. IF (ISI WOS 2021): 8.315. Citazioni: 3

    9) Yaqi Qiu, Federica Maione, Stefania Capano, Claudia Meda, Orietta Picconi, Serena Brundu, A lberto Pisacane, Anna Sapino, Clelia Palladino, Giovanni Barillari, Paolo Monini, Federico Bussolino, Barbara Ensoli, Cecilia Sgadari, and Enrico Giraudo. HIV-protease inhibitors block HPV16-induced murine cervical carcinoma and promote vessel normalization in association with MMP-9 inhibition and TIMP-3 induction. Mol Cancer Ther, 2020; 19(12):2476–89. doi: 10.1158/1535-7163.MCT-20-0055. Corresponding author. IF (ISI WOS 2021): 6.261

    10) Sandra Atlante, Alessia Visintin, Elisabetta Marini, Matteo Savoia, Chiara Dianzani, Marta Giorgis, Duran Sürün, Federica Maione, Frank Schnütgen, Antonella Farsetti, Andreas M. Zeiher, Massimo Bertinaria, Enrico Giraudo, Francesco Spallotta, Chiara Cencioni and Carlo Gaetano. α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death Dis. 2018; 9(7):756. doi: 10.1038/s41419-018-0802-8. IF (ISI WOS 2021): 8.469. Citazioni: 21.

    11) Noemi Gioelli, Federica Maione, Chiara Camillo, Michela Ghitti, Donatella Valdembri, Noemi Morello, Marie Darche, Lorena Zentilin, Gabriella Cagnoni, Yaqi Qiu, Mauro Giacca, Maurizio Giustetto, Michel Paques, Ilaria Cascone, Giovanna Musco, Luca Tamagnone, Enrico Giraudo*, Guido Serini*. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci Transl Med. 2018; 10(442):eaah4807. doi: 10.1126/scitranslmed.aah4807. *Co-Corresponding author and Co-last author.  IF (ISI WOS 2021): 17, 956. Citazioni: 25.

    12) Dettori D, Orso F, Penna E, Baruffaldi D, Brundu S, Maione F, Turco E, Giraudo E, Taverna D. Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. Mol Ther. 2018; 26(8):2008-2018. doi: 10.1016/j.ymthe.2018.05.020. IF (ISI WOS 2021): 11.454. Citazioni: 13.

    13) Kunita A, Baeriswyl V, Meda C, Cabuy E, Takeshita K, Giraudo E, Wicki A, Fukayama M, Christofori G. Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front. Am J Pathol. 2018; 188(5):1276-1288. doi: 10.1016/j.ajpath.2018.01.016. Epub 2018 Feb 17. IF (ISI WOS 2021): 4.307. Citazioni: 11.

    14) Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017; 552(7683):116-120. doi: 10.1038/nature24673. IF (ISI WOS 2021): 49,962. Citazioni: 216.

    15) Zoi Diamantopoulou, Maud-Emmanuelle Gilles, Maha Sader, Mélissande Cossutta, Benoit Vallée, Claire Houppe, Damien Habert, Blandine Brissault, Eric Leroy, Federica Maione, Enrico Giraudo, Damien Destouches, Jacques Penelle, José Courty1, and Ilaria Cascone. Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy. Oncotarget. 2017; 8(52):90108-90122. doi: 10.18632/oncotarget.21441. eCollection 2017. IF (ISI WOS 2017): 5.168. Citazioni: 11.

    16) Regano D, Visintin A, Clapero F, Bussolino F, Valdembri D, Maione F, Serini G, *Giraudo E. Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program. Arterioscler Thromb Vasc Biol. 2017; Sep; 37(9):1710-1721. doi: 10.1161/ATVBAHA.117.308226. *Corresponding author and last author. IF (ISI WOS 2021): 8,311. Citazioni: 5.

    17) Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, Houppe C, Destouches D, Shchors K, Prochasson C, Mongelard F, Lamba S, Bardelli A, Bouvet P, Couvelard A, Courty J, Giraudo E*, Cascone I*. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 2016; Dec 15; 76(24):7181-7193. doi: 10.1158/0008-5472.CAN-16-0300. *Co-Corresponding author and Co-last author. IF (ISI WOS 2021): 12,701. Citazioni: 52.

    18) Avanzato D, Genova T, Fiorio Pla A, Bernardini M, Bianco S, Bussolati B, Mancardi D, Giraudo E, Maione F, Cassoni P, Castellano I, Munaron L.  Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling. Sci Rep. 2016; Sep 2; 6:32602. doi: 10.1038/srep32602. IF (ISI WOS 2021): 4.379. Citazioni: 40.

    19) Valdembri D, Regano D, Maione F, Giraudo E*, Serini G. Class 3 semaphorins in cardiovascular development Cell Adh Migr. 2016; Nov; 10(6):641-651. doi: 10.1080/19336918.2016.1212805.  *Co-Corresponding author and Co-last author. IF (ISI WOS 2021): 3.405. Citazioni: 20.

    20) Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med. 2016; May 5; 14(1):119. doi: 10.1186/s12967-016-0872-2. IF (ISI WOS 2021): 5.531;. Citazioni: 8.

    21) Federica Maione, Simonetta Oliaro-Bosso, Claudia Meda, Federica Di Nicolantonio, Federico Bussolino, Gianni Balliano, *Franca Viola and Enrico Giraudo*. The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.  Sci. Rep. 2015; Mar 12; 5:9054; doi:10.1038/srep09054. *Corresponding author. IF (ISI WOS 2021): 4.379. Citazioni: 26.

    22) Federica Maione and Enrico Giraudo. Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer. Methods Mol Biol., 2015; 1267:349-65. doi: 10.1007/978-1-4939-2297-0_17. Citazioni: 6. Sopus :2-s2.0-84954582641. *Last and Co-corresponding author 

    23) Patella F, Schug ZT, Persi E, Neilson LJ, Erami Z, Avanzato D, Maione F, Hernandez-Fernaud JR, Mackay G, Zheng L, Reid S, Frezza C, Giraudo E, Fiorio Pla A, Anderson K, Ruppin E, Gottlieb E, Zanivan S. Proteomics-based metabolic modelling reveals that fatty acid oxidation controls endothelial cell permeability. Mol Cell Proteomics. 2015. Mar; 14(3):621-34. doi: 10.1074/mcp.M114.045575. IF (ISI WOS 2021): 5,911. Citazioni: 55.

    24) Corà D, Astanina E, Giraudo E, Bussolino F. Semaphorins in cardiovascular medicine. Trends Mol Med. 2014; Oct; 20(10):589-98. doi: 10.1016/j.molmed.2014.07.005. IF (ISI WOS 2021): 11.951. Citazioni: 10.

    25) Valetti S, Maione F, Mura S, Stella B, Desmaële D, Noiray M, Vergnaud J, Vauthier C, Cattel L,Giraudo E, Couvreur P. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. J Control Release. 2014; Oct, 28;192:29-39. doi: 10.1016/j.jconrel.2014.06.039. IF (ISI WOS 2021): 9.776. Citazioni: 43.

    26) Bussolino F, Giraudo E, Serini G. Class 3 semaphorin in angiogenesis and lymphangiogenesis. Chem Immunol Allergy. 2014; 99:71-88. doi: 10.1159/000353315. Citazioni: 10. Scopus: 2-s2.0-84904229357

    27) Zanivan S, Maione F, Hein MY, Hernández-Fernaud JR, Ostasiewicz P, Giraudo E, Mann M. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics. 2013; Dec; 12(12):3599-611. doi: 10.1074/mcp.M113.031344. IF (ISI WOS 2021): 5,911. Citazioni: 45.

    28) Gu C, Giraudo E*. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res. 2013; May 15; 319(9):1306-16. doi: 10.1016/j.yexcr.2013.02.003. *Corresponding author. IF (ISI WOS 2021):  3,905.  Citazioni: 78. 

    29) Guido Serini, Federico Bussolino, Federica Maione and Enrico Giraudo*. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. J. Intern. Med. 2013; Feb; 273(2):138-55.  doi: 10.1111/joim.12017. * Corresponding author. IF (ISI WOS 2021): 8.989. Citazioni: 32.

    30) Carrer A, Moimas S, Zacchigna S, Pattarini L, Zentilin L, Ruozzi G, Mano M, Sinigaglia M, Maione F, Serini G, Giraudo E, Bussolino F, Giacca M. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res, 2012, Dec 15; 72:6371-6381. doi: 10.1158/0008-5472.CAN-12-0762.  IF (ISI WOS 2021): 12,701. Citazioni: 43.

    31) Napione L, Strasly M, Meda C, Mitola S, Alvaro M, Doronzo G, Marchiò S, Giraudo E, Primo L, Arese M, Bussolino F.  IL-12-dependent innate immunity arrests endothelial cells in G0-G1 phase by a p21(Cip1/Waf1)-mediated mechanism. Angiogenesis. 2012; Dec; 15(4):713-25. doi: 10.1007/s10456-012-9286-9. IF (ISI WOS 2021): 9.596. Citazioni: 3.

    32) Federica Maione, Stefania Capano, Donatella Regano, Lorena Zentilin, Mauro Giacca, Oriol Casanovas, Federico Bussolino, Guido Serini, and Enrico Giraudo1. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 2012; May 1; 122(5):1832-48. doi: 10.1172/JCI58976. 1 Corresponding author. IF (ISI WOS 2021): 14.808. Citazioni: 123.

    33) Claudia Meda, Fabiola Molla, Maria De Pizzol, Donatella Regano, Federica Maione, Stefania Capano, Massimo Locati, Alberto Mantovani, Roberto Latini, Federico Bussolino and Enrico Giraudo1. Sema4A exerts a pro-angiogenic effect by enhancing VEGF-A expression in macrophages. J. Immunol. 2012; Apr 15; 188 (8); 4081-92. doi: 10.4049/jimmunol.1101435. 1 Corresponding author. IF (ISI WOS 2021): 5,422. Citazioni: 48.

    34) Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med. 2012; Mar; 4(3):234-50. doi: 10.1002/emmm.201100205. IF (ISI WOS 2021): 12.137. Citazioni: 69.

    35) Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. (2011);  Feb; 47(3):479-90. doi: 10.1016/j.ejca.2010.10.003. IF (ISI WOS 2021): 9.162. Citazioni: 37.

    36) Primo L, Seano G, Roca C, Maione F, Gagliardi PA, Sessa R, Martinelli M, Giraudo E, di Blasio L, Bussolino F. Increased expression of α6 integrin in endothelial cells unveils a proangiogenic role for basement membrane. Cancer Res. 2010; Jul; 70(14): 5759-69. doi: 10.1158/0008-5472.CAN-10-0507. IF (ISI WOS 2021): 12,701. Citazioni: 41.

    37) Federica Maione, Fabiola Molla, Roberto Latini, Lorena Zentilin, Mauro Giacca, Claudia Meda, Giorgio Seano, Guido Serini, Federico Bussolino and Enrico Giraudo1. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin.Invest. 2009; Nov; 119(11): 3356-72. doi: 10.1172/JCI36308. 1 Corresponding author. IF (ISI WOS 2021): 14.808. Citazioni: 166.

    38) Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto G. Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol. Lipids. 2009; Oct; 44(10):907-916. doi: 10.1007/s11745-009-3338-y. IF (ISI WOS 2021): 1.880. Citazioni: 46.

    39) Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. Angiogenesis, 2009; May, 12(2):195. Erratum to: Angiogenesis DOI 10.1007/s10456-009-9138-4; 2009;12(2):187-93. doi: 10.1007/s10456-009-9138-4. IF (ISI WOS 2021): 9.596. Citazioni: 41.

    40) Francesca Orso, Elisa Penna, Daniela Cimino, Elena Astanina, Federica Maione, Donatella Valdembri, Enrico Giraudo, Guido Serini, Piero Sismondi, Michele De Bortoli and Daniela Taverna. AP-2a and AP-2g Regulate Epithelial Tumor Progression via Specific Genetic Programs. FASEB J, 2008; Aug, 22(8):2702-14. doi: 10.1096/fj.08-106492. IF (ISI WOS 2021): 5.191. Citazioni: 52.

    41) Lianglin Zhang, Enrico Giraudo, Jason A. Hoffman, Douglas Hanahan and Erkki Ruoslahti. Lymphatic Zip Codes in Tumors and Premalignant Lesions. Cancer Res. 2006; Jun 1; 66(11):5696-706. doi: 10.1158/0008-5472.CAN-05-3876. IF (ISI WOS 2020): 12,701. Citazioni: 61.

    42) Dylan Daniel, Christopher Chiu, Enrico Giraudo, Masahiro Inoue, Lee A. Mizzen, N. Randall Chu and Douglas Hanahan. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005; Mar 1, 65(5):2018-25. doi: 10.1158/0008-5472.CAN-04-3444. IF (ISI WOS 2020): 12,701. Citazioni: 65.

    43) Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis". J. Clin. Invest. (2004); Sep 1, 114(5):623-33. doi: 10.1172/JCI22087. IF (ISI WOS 2020): 14.808. Citazioni: 522.

    44) Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; May, 5(5):443-53; doi: 10.1016/s1535-6108(04)00111-4. IF (ISI WOS 2021): 31.743. Citazioni: 481. 

    45) Hoffman JA*, Giraudo E*, Singh M, Zhang L, Inoue M, Porkka K, Hanahan D, Ruoslahti E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 2003; Nov, 4(5):383-91. doi: 10.1016/s1535-6108(03)00273-3. *First author co-autorship.  IF (ISI WOS 2021): 31.743. Citazioni: 180. 

    46) Ilaria Cascone *, Enrico Giraudo *, Francesca Caccavari, Lucia Napione, Elisa Bertotti, John G. Collard, Guido Serini and Federico Bussolino. Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network. Adherens junctions and myosin light chain as targets of Rac1 and RhoA. J Biol Chem. 2003; Dec, 278(50):50702-13. doi: 10.1074/jbc.M307234200. * First author co-autorship. IF (ISI WOS 2021): 5,517. Citazioni: 65. 

    47) Cascone I, Audero E, Giraudo E, Napione L, Maniero F, Philips MR, Collard JG, Serini G, Bussolino F. Tie-2 - dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood. 2003; Oct 1, 102(7):2482-90. doi: 10.1182/blood-2003-03-0670. IF (ISI WOS 2021): 22.113. Citazioni: 47. 

    48) Serini G*, Ambrosi D*, Giraudo E* Gamba A*, Preziosi L, Bussolino F. "Modeling the early stages of vascular network assembly". EMBO J. (2003); Apr, 22(8):1771-9. doi: 10.1093/emboj/cdg176. *First author co-autorship. IF (ISI WOS 2021): 11.598. Citazioni: 230. 

    49) Corallini A, Possati L, Trabanelli C, Giraudo E, Rocchetti R, Talevi S, Caputo A, Bussolino F, Barbanti-Brodano G.. Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-b1. Carcinogenesis. 2003; 24(9):1435-44. doi: 10.1093/carcin/bgg096. IF (ISI WOS 2021): 4.944. Citazioni: 8.

    50) Gamba A, Ambrosi D, Coniglio A, de Candia A, Di Talia S, Giraudo E, Serini G, Preziosi L, Bussolino F. Percolation, morphogenesis, and burgers dynamics in blood vessels formation. Phys Rev Lett. 2003; Mar 21; 90(11):118101. doi: 10.1103/PhysRevLett.90.118101. IF (ISI WOS 2020): 9.161. Citazioni: 166.

    51) Del Sorbo, M. Arese, Giraudo E., M. Tizzani, L. Biancone, F.Bussolino, G.Camussi. "Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol. 2001; Feb; 31(2):376-383. doi: 10.1002/1521-4141(200102)31:2<376::aid-immu376>3.0.co;2-5. IF (ISI WOS 2021):  5.532. Citazioni: 22.

    52) Cutrupi S, Baldanzi G, Gramaglia D, Maffe A, Schaap D, Giraudo E, van Blitterswijk W, Bussolino F, Comoglio PM, and Graziani A. "Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility". EMBO J. 2000; Sep 1; 19(17):4614-22. doi: 10.1093/emboj/19.17.4614. IF (ISI WOS 2021): 11.598. Citazioni: 79.

    53) Giraudo E., Primo L., Audero E., Gerber HP, Koolwijk P., Soker S., Klagsbrun M Ferrara N, and. Bussolino F. "Tumor necrosis factor-a regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells". J. Biol. Chem., 1998; Aug 21; 273(34):22128-35. doi: 10.1074/jbc.273.34.22128. IF (ISI WOS 2021): 5,157. Citazioni: 229.

    54) A. Albini, R. Soldi, D. Giunciuglio, E. Giraudo, R. Benelli, L. Primo, D. Noonan, M. Salio, G. Camussi, W. Rockl and F. Bussolino. "The angiogenesis induced by HIV-1 Tat protein is mediated by the flk-1/KDR receptor on vascular endothelial cells". Nature Med. 1996, Dec; 2(12):1371-75. doi: 10.1038/nm1296-1371. IF (ISI WOS 2020): 36.130. Citazioni: 333.

    55) Giraudo E., M. Arese, C Toniatti, M Stransly, L Primo, A Mantovani, G Ciliberto and F. Bussolino. "Interleukin-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells." J. Immunol. 1996; Sep 15; 157(6):2618-23; WOS:A1996VL10300049; ISSN: 1550-6606. IF (ISI WOS 2021): 5,422. Times cited: 52.

    56) F. Silvagno, A. Follenzi, M. Arese, M. Prat, E. Giraudo, G. Gaudino, G. Camussi, P. M. Comoglio, F. Bussolino. "In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis". Arterioscler. Thromb. Vasc. Biol. 1995; Nov; 15(11):1857-65. doi: 10.1161/01.atv.15.11.1857. IF (ISI WOS 2021): 8,311. Times cited: 85. 

    Toulouse, France, 23-24 Ottobre 2019. Pancreatic Cancer Symposium, Association Française Pour La Recherche Sur Le Cancer Du Pancréas (AFRC). relatore su invito, titolo del seminario: Targeting Semaphorin4A-expressing myeloid cells to impair the progression of pancreatic ductal adenocarcinoma.

    Baveno, Italy, 25-28 Maggio 2019. Embo Workshop- Neural guidance molecules in development and disease; relatore su invito, titolo del seminario: Targeting Semaphorin4A-expressing myeloid cells to impair cancer progression”.

    Reims, France, 14-16 Ottobre 2018. 8eme Congrès de la Société Française d’Angiogenèse 2018. Relatore su invito; titolo del seminario: “Targeting Semaphorins to normalize the tumor vasculature and block the metastatic growth”.

    Paris, France 20-22 Settembre 2018.  ImmunoRad - the international conference on immunotherapy radiotherapy combination; relatore su invito, titolo del seminario: “Macrophages reprogramming modulates the immune tumor microenvironment in mouse models of HPV-driven cervical cancer”.

    1. Lausanne, Svitzerland, October 6th 2015. ISREC/SCCL special seminar. Seminario dal titolo: "Macrophage "re-education" induced by zoledronic acid impairs tumor angiogenesis and metastatic dissemination in a mouse model of spontaneous cervical cancer".

    2. S. Diego, CA, USA, aprile 5-9, 2014. 105rd AACR Annual Meeting 2014. Symposium "Tumor angiogenesis". Seminario dal titolo: "Zoledronic acid overcomes the resistance to the anti-angiogenic therapy and normalizes tumor vessels by switching from a M2- to a M1-like macrophages phenotype in a mouse model of spontaneous cervical cancer".

    3. Amsterdam, The Netherlands 12-14 Marzo 2014. 5th International Meeting on Angiogenesis, VU University Medical Center. Seminario dal titolo: "Zoledronic acid normalizes tumor vessels and blocks metastasis formation by skewing macrophages from a M2 to an M1-like phenotype in a mouse model of spontaneous cervical cancer.

    4. Pontignano, Siena, Italia, 13-15 maggio 2013. Angiogenesi: basi molecolari e implicazioni terapeutiche IV. Seminario dal titolo: " Sema 3A: a new tool to normalize the tumor vasculature and to impair metastasi dissemination".

    5. Lausanne, Switzerland, 5 Febbraio 2013. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences. Swiss Federal Institute of Technology Lausanne (EPFL). Lecture dal titolo " Semaphorin 3A: a new tool to "normalize" the tumor microenvironment and to block metastasis dissemination".

    6. Trieste, Italia, Novembre 29 2012. International Centre for Genetic Engineering and Biotechnology (ICGEB). Seminario dal titolo: "Semaphorin 3A: a new tool to normalize the tumor vasculature and to block metastasi dissemination".

    7. Chicago, Illinois, USA, 31 marzo- 4 aprile, 2012. 103rd AACR Annual Meeting 2012. Major Symposium "Vascular Reprogramming to improve Clinical Outcome". Seminario dal titolo: "Targeting semaphorin 3A: a new tool to normalize tumor vasculature and to overcome the evasive resistance to antiangiogenic therapy".   

    8. Lausanne, Switzerland, 7-10 settembre 2011. SREC Symposium 2011 Hallmarks and Horizons of Cancer. Seminario dal titolo: "Semaphorin 3A blocks cancer invasiveness and metastases dissemination induced by the anti-angiogenic therapy by overcoming tumor hypoxia".

    9. Pontignano, Italia, 10-12 maggio 2010. Workshop SIICA, "Angiogenesi: basi molecolari ed implicazioni terapeutiche III". Seminario dal titolo: "In vivo targeting semaphorins: new tools to control tumor angiogenesis and tumor invasiveness".

    10. Lausanne, Switzerland, 2 Febbraio 2010. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences. Swiss Federal Institute of Technology Lausanne (EPFL). Lecture dal titolo: "In vivo targeting semaphorins: new tools to control tumor angiogenesis".

    11. Roma, Italia, 15-16 gennaio 2010. International Conference "in memory of Judah Folkman "Update on angiogenesis: translational research". Seminario dal titolo: "In vivo targeting semaphorins: new tools to control tumour angiogenesis".

    12. Parigi, Francia, 27 aprile 2009. Marie Curie Institute, Parigi; Lecture dal titolo: " In vivo targeting semaphorins: new tools to control tumor angiogenesis."

    13. Roma, Italia, 24 gennaio 2009. "Update on Angiogenesis: One year from the departure of Judah Folkman". Seminario dal titolo: "Semaphorins and tumor angiogenesis".

    14. San Francisco, CA, USA, 12-15 gennaio 2009. "Mouse Models of Cancer", AACR special conference in cancer Research. Seminario dal titolo: "Semaphorin 3A Regulates Angiogenesis and Tumor Progression in Mouse Models of Tumorigenesis".

    15. Riccione, Italia 26-28 settembre 2007. Congresso SIB2007. "Cellular Biochemistry". Seminario dal titolo: "Role of class 3 semaphorins in tumor angiogenesis in transgenic mouse models of carcinogenesis".

    16. Rod Island, Newport, USA, 19-24 Agosto 2007. Salve Regina University, Gordon Conference on Angiogenesis. Seminario dal titolo: "Role of class 3 semaphorins in tumor angiogenesis in transgenic mouse models of pancreatic and cervical carcinogenesis".

    17. Riccione, Italia 28-30 settembre 2006. Congresso SIB2007. "Cellular Biochemistry". Seminario dal titolo: "Molecular changes in lymphatic vessels during tumor progression"

    18. Davos, Switzerland, 22 - 25 marzo, 2006. Eighth and Valedictory Workshop on Bisphosphonates From the Laboratory to the Patient. Seminario dal titolo: "Anti-angiogenic effects of bisphosphonates".

    19. Cervo Ligure, Italy, 6-8 ottobre 2005. Cervo Preclinical Working Conference (CPWC). Seminario dal titolo: "Aminobisphosphonates inhibit angiogenesis and impairs carcinogenesis in a mouse model of cervical carcinogenesis".

    20. Milano, Italia, 11-14 marzo, 2004. "First IEO-IFOM meeting on cancer". Seminario dal titolo: "A bisphosphonate inhibits angiogenesis and impairs cervical carcinogenesis by targeting MMP-9 activity and its expression in infiltrating macrophages".  

    Organized Meetings, conferences and workshop

     Workshop at Lorenz Center, October 4-8th 2010, Leiden, The Netherlands. Scientific organizer of the workshop: "Modelling angiogenesis: joining cells, maths and computers".

     

    - Since 2009 we are collaborating with prof. Doug Hanahan, at the Swiss Institute for Experimental Cancer Research (ISREC), at the École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland. 

    The aim of the collaboration is to assess the role of microRNAs in regulating metastases formation and their role during anti-angiogenic therapies by using in vivo AAV8 delivery system to assess their functional role.

    -Since 2010 we are collaborating with Dr. Oriol Casanovas, Catalan Institute of Oncology, (ICO), Barcelona, Spain.

    The aim of the collaboration is to study the role of class 3 Semaphorins in regulating the evasive resistance to the anti-angiogenic therapies induced by anti-VEGF drugs.

    -Since 2009 we are collaborating with Dr. Sara Zanivan,  Vascular Proteomics lab, Beatson Institute for Cancer Research, Glasgow, UK  and prof. Matthias Mann, Max-Planck Institute for Biochemistry, Martinsried, Germany.

    We are investigating the role of CLEC14A as new target for anti-angiogenic therapy by using transgenic mouse models of tumorigenesis.

    -Since 2008 we are collaborating with Dr. Ansgar Santel, Silence Therapeutic Inc., Berlin, Germany. The aim of this collaboration is to investigate the effect and role of AtuPLEX-PEG, nano-particles (NPs) containing siRNA of molecule the ragulate tumor-angigoenesis. the main goal is to use this NPs to deliver in vivo siRNA against pro-angiogenic factors in transgenic mouse models of tumorigenesis  to inhibit angiogenesis and tumor progression.

    Since 2006 my group is collaborating with Prof. Mauro Giacca, at International Centre for Genetic Engineering and Biotechnology (ICGEB), Molecular Medicine Laboratory, Trieste, Italy. This collaboration is aimed to develop and employ a somatic gene transfer in pancreas of RIP-Tag2 and PDAC tumor mouse models by means of adeno-associated virus (AVV)-8. We have recently developed this technology by infecting therapeutic genes in a transgenic mouse models of cervical cancer (HPV16/E2).

     

     

     

    Research groups

    Research projects

    Academic bodies

    Office hours

    Tutti i giorni previo appuntamento

    Announcements

    Esito scritto di Biochimica (CTF) del 25/11/2024: orale 5/12, ore 10,00, aula C

    Faculty

    Last update: 14/10/2024 16:11
    Non cliccare qui!